About Genmab » Genmab's Senior Management Team

Genmab's Senior Management Team

Jan van de Winkel

Prof. Jan G. J. van de Winkel, Ph.D.

Dutch
President & Chief Executive Officer
Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. Dr. van de Winkel has over 20 years of experience in the therapeutic antibody field and served as Scientific Director and Vice President of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 40 patents and pending patent applications. He is a part-time Professor of Immunology at Utrecht University and also a member of the Advent Life Sciences advisory board, the scientific advisory board of Thuja Capital Healthcare Fund, and the independent advisory board of Clear River Capital. He holds M.S. and Ph.D. degrees from the University of Nijmegen.

David Eatwell

David A. Eatwell, FCCA

British
Executive Vice President & Chief Financial Officer
Mr. Eatwell joined Genmab in 2008 with extensive experience and a proven track record in leading international life science businesses, having spent 15 years working in Europe and 10 years in the US. Most recently, Mr. Eatwell served as Chief Financial Officer of Catalent Pharma Solutions, Inc., a USD 1.8 billion leading provider of manufacturing and packaging services for the pharmaceutical and biotech industry, with 33 facilities in 12 countries and 10,000 employees. Prior to Catalent Mr. Eatwell served as a divisional CFO of Cardinal Health, Inc., a fortune 20 global manufacturer and distributor of healthcare products and services, where he spearheaded the USD 3.3 billion sale of the Pharmaceutical Technologies and Services division to The Blackstone Group and was instrumental in creating the framework and building the infrastructure to support the newly created company, Catalent Pharma Solutions, Inc.  Mr. Eatwell is a member of the Association of Chartered Certified Accountants.

Ole Baadsgaard, M.D. Dr.MSci.

Danish
Senior Vice President, Medical Affairs
Dr. Baadsgaard has been a member of Genmab's Scientific Advisory Board since our inception. He joined Genmab as Medical Director in 2000 and in 2008 he was appointed Senior Vice President, Medical Affairs. Dr. Baadsgaard is a Board Certified Specialist in dermatology and has extensive clinical and scientific experience from both Denmark and the US. He is author of 100+ scientific peer-reviewed publications within clinical research and is named inventor on over 15 patents and patent applications. He received his M.D. degree from the University of Aarhus and his Dr.MSci. degree from the University of Copenhagen.

Paul W.H.I. Parren, Ph.D.

Dutch
Senior Vice President, Research & Pre-Clinical Development
Dr. Parren joined Genmab in 2002 and was appointed Senior Vice President in 2008. Previously he was an Associate Professor in the Department of Immunology at The Scripps Research Institute in La Jolla, California. He is author of 100+ scientific publications in the antibody field and is named inventor on over 20 patents and patent applications. He holds M.S. and Ph.D. degrees from the University of Amsterdam.

Barry B. Littlejohns

British
Senior Vice President, Head of Business Development & Operations
Mr. Littlejohns joined Genmab in 2009 with extensive experience in leading international life science businesses, having spent 10 years working in Europe and 10 in the USA. Most recently, Mr. Littlejohns served as Vice President, Global Business Operations at Catalent Pharma Solutions, Inc., a leading provider of manufacturing and packaging services for the pharmaceutical and biotech industry. While at Catalent Mr. Littlejohns was responsible for four manufacturing facilities and Commercial affairs, identifying and evaluating commercial growth opportunities and developing and implementing cost saving systems, processes and initiatives. Prior to joining Catalent, Mr. Littlejohns served as Vice President and General Manager at Cardinal Health where he was responsible for two facilities. Mr. Littlejohns earned a Finance and Business Degree from Swindon college.

Birgitte Stephensen, M.Sc.

Danish
Senior Vice President, IPR & Legal
Ms. Stephensen joined Genmab in 2002 and was appointed Senior Vice President in 2010. Ms. Stephensen has extensive experience from both private practice and industry working with intellectual property matters within the pharmaceutical and biotech field. Ms. Stephensen passed the European Qualifying Examination as European Patent Attorney in 1994. She earned a M.Sc. from the Danish University of Pharmaceutical Sciences.

Michael K. Bauer, Ph.D.

German
Senior Vice President, Clinical Development
Dr. Bauer joined Genmab in 2006 and was appointed Senior Vice President in 2010. Before joining Genmab, Dr. Bauer held various positions in academia, the pharmaceutical industry and the venture finance sector in Germany, New Zealand, U.S.A. and Denmark. He is author of 50+ scientific publications. He earned a M.Sc. from the University of Stuttgart-Hohenheim and a Ph.D. degree from the University of Göttingen, Germany.